ArticleAlzheimer's research & therapy2021
In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease.
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Association between amyloid-β deposition and cognitive function in cognitively normal adults: a multilevel meta-analysis.Alzheimer's research & therapy · 2026Pooled it
- Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts.bioRxiv : the preprint server for biology · 2026Article
- Gene-Modulated Network Diffusion for Improved Modeling of Amyloid-bioRxiv : the preprint server for biology · 2026Article
- Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.Annals of neurology · 2025Article
- Brain Topological Changes in Subjective Cognitive Decline and Associations with Amyloid Stages.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- AI-powered integration of multimodal imaging in precision medicine for neuropsychiatric disorders.Cell reports. Medicine · 2025Review
- Establishing Regional Aβ Cutoffs and Exploring Subgroup Prevalence Across Cognitive Stages Using BeauBrain AmyloDementia and neurocognitive disorders · 2025Article
- Relationship between regional relative theta power and amyloid deposition in mild cognitive impairment: an exploratory study.Frontiers in neuroscience · 2025Article
- Association of precuneus Aβ burden with default mode network function.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Rethinking neuropsychological test validity in dementia assessment: a critical review in the age of neuroimaging and digital markers.Frontiers in human neuroscience · 2025Review
- Characterizing Amyloid Pathogenic Spread in Alzheimer's Disease Through A Network Diffusion Model.ACM-BCB ... ... : the ... ACM Conference on Bioinformatics, Computational Biology and Biomedicine. ACM Conference on Bioinformatics, Computational Biology and Biomedicine · 2025Article
- Associations of cerebral amyloid beta and tau with cognition from midlife.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Spatial extent as a sensitive amyloid-PET metric in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- In a circuit necessary for cognition and emotional affect, Alzheimer's-like pathology associates with neuroinflammation, cognitive and motivational deficits in the young adult TgF344-AD rat.Brain, behavior, & immunity - health · 2024Article
- Biomarker-based staging of Alzheimer disease: rationale and clinical applications.Nature reviews. Neurology · 2024Review
- Neuropsychiatric Profiles and Cerebral Amyloid Burden in Adults without Dementia.Dementia and geriatric cognitive disorders · 2024Article
- The foundation and architecture of precision medicine in neurology and psychiatry.Trends in neurosciences · 2023Review
- Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer's Disease Prior to Overt Global Amyloid Positivity.Journal of Alzheimer's disease : JAD · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
backgroundWe investigated regional amyloid staging characteristics in
methodsWe analyzed partial volume effect-corrected
resultsThe staging model suggested progressive accumulation of amyloid from associative to primary neocortex and gradually involving subcortical regions. Longitudinal PET measurements supported the cross-sectionally estimated amyloid progression. In mixed-effects longitudinal analysis of cognitive follow-up data obtained over an average period of 6.5 years following the baseline PET measurement, amyloid stage II showed a faster decline in executive function, and advanced amyloid stages (III and IV) showed a faster decline across multiple cognitive domains compared to stage 0.
conclusionsOverall, the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.